This OOC design has allowed to demonstrate the superior anticancer activity of the DNA demethylating agent Decitabine (DAC) when administered with Interferon-α (IFN-α) against melanoma in a competitive assay (Lucarini et al., 2017). The gene discussed is IFNA1; the disease is melanoma.